Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision Oncology

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Cancer research faces challenges due to complex signaling pathways like MAPK, PAM, and Wnt/β-catenin.
• Tumor genetic alterations converge on core pathways but diverge downstream, causing therapeutic resistance via EMT, immune evasion, and metabolic reprogramming.

Purpose of the Study:

• To synthesize convergent and divergent signaling pathways into a clinically actionable framework for precision oncology.
• To critically assess current precision oncology strategies and identify gaps in addressing therapeutic resistance.
• To propose a dual-axis model integrating genomic profiling and dynamic signaling evolution for precision therapy.

Main Methods:

• Literature review synthesizing existing research on cancer signaling pathways.
• Critical assessment of current precision oncology strategies and their limitations.
• Development of a novel dual-axis model for precision therapy informed by pathway dynamics.

Main Results:

• Identified convergence and divergence of key cancer signaling pathways (MAPK, PAM, Wnt/β-catenin).
• Highlighted mechanisms of therapeutic resistance including EMT, immune evasion, and metabolic reprogramming.
• Proposed a dual-axis model integrating static genomic data with dynamic signaling for clinical application.

Conclusions:

• A novel framework synthesizing pathway convergence and divergence offers clinical insights for precision oncology.
• The proposed dual-axis model provides a roadmap for developing combination therapies to overcome adaptive resistance.
• Future research should focus on leveraging pathway interdependencies and dynamic signaling to enhance cancer treatment efficacy.